Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bluebird bio (BLUE) stocks

Learn how to easily invest in Bluebird bio stocks.

Bluebird bio is a biotechnology business based in the US. Bluebird bio stocks (BLUE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $30.43 – a decrease of 3.78% over the previous week. Bluebird bio employs 323 staff and has a trailing 12-month revenue of around $4 million.

How to buy Bluebird bio stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BLUE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners


National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Bluebird bio stock price (NASDAQ:BLUE)

Use our graph to track the performance of BLUE stocks over time.

Bluebird bio shares at a glance

Information last updated 2023-05-27.
Latest market close$3.56
52-week range$2.78 - $8.58
50-day moving average $3.81
200-day moving average $5.85
Wall St. target price$6.90
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.47

Buy Bluebird bio stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy Bluebird bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bluebird bio price performance over time

Historical closes compared with the close of $3.56 from 2023-05-26

1 week (2023-05-23) -3.78%
1 month (2023-04-28) -18.16%
3 months (2023-03-02) -28.08%
6 months (2022-11-30) -54.30%
1 year (2022-05-26) N/A
2 years (2021-05-28) -88.56%
3 years (2020-05-29) 63.63
5 years (2018-05-30) 182.8

Is Bluebird bio stock undervalued or overvalued?

Valuing Bluebird bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bluebird bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bluebird bio financials

Revenue TTM $4 million
Gross profit TTM $-247,244,000
Return on assets TTM -16.19%
Return on equity TTM -39.87%
Profit margin 0%
Book value $3.34
Market capitalisation $378.8 million

TTM: trailing 12 months

Bluebird bio share dividends

We're not expecting Bluebird bio to pay a dividend over the next 12 months.

Have Bluebird bio's shares ever split?

Bluebird bio's shares were split on a 1544:1000 basis on 5 November 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1544 shares. This wouldn't directly have changed the overall worth of your Bluebird bio shares – just the quantity. However, indirectly, the new 35.2% lower share price could have impacted the market appetite for Bluebird bio shares which in turn could have impacted Bluebird bio's share price.

Bluebird bio share price volatility

Over the last 12 months, Bluebird bio's shares have ranged in value from as little as $2.78 up to $8.58. A popular way to gauge a stock's volatility is its "beta".

BLUE.US volatility(beta: 0.93)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bluebird bio's is 0.9296. This would suggest that Bluebird bio's shares are less volatile than average (for this exchange).

Bluebird bio overview

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc. , and changed its name to bluebird bio, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site